These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 1251394)

  • 21. [A case of mental change resulting from L-dopa treatment].
    Gulmann NC
    Ugeskr Laeger; 1976 Oct; 138(41):2497-8. PubMed ID: 973254
    [No Abstract]   [Full Text] [Related]  

  • 22. [Experiences in the treatment of Parkinsonism using a combination of L-dopa and alpha-methyldopa-hydrazine].
    Vymazal J; Roth B; Nevsímal O
    Cesk Neurol Neurochir; 1976 Mar; 39(2):59-62. PubMed ID: 1260921
    [No Abstract]   [Full Text] [Related]  

  • 23. Zotepine in levodopa-induced Psychosis.
    Spieker S; Stetter F; Klockgether T
    Mov Disord; 1995 Nov; 10(6):795-7. PubMed ID: 8750001
    [No Abstract]   [Full Text] [Related]  

  • 24. Editorial: Dopa decarboxylase inhibitors.
    Br Med J; 1974 Nov; 4(5939):250-1. PubMed ID: 4425849
    [No Abstract]   [Full Text] [Related]  

  • 25. [Tiapride in persistent dyskinesias following long-term L-dopa for parkinsonism].
    Arlazoroff A; Flechtir S; Goldexberg E; Bleicher Z; Barber Y
    Harefuah; 1985 Mar; 108(5):227-9. PubMed ID: 4007677
    [No Abstract]   [Full Text] [Related]  

  • 26. Treatment of drug-induced psychosis in Parkinson's disease with clozapine.
    Greene P; Cote L; Fahn S
    Adv Neurol; 1993; 60():703-6. PubMed ID: 8420214
    [No Abstract]   [Full Text] [Related]  

  • 27. A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients.
    Libman I; Gawel MJ; Riopelle RJ; Bouchard S
    Can J Neurol Sci; 1987 Nov; 14(4):576-80. PubMed ID: 3319120
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Levodopa and amantadine in the treatment of Parkinsonism.
    Critchley E
    Practitioner; 1972 Apr; 208(246):499-504. PubMed ID: 5031037
    [No Abstract]   [Full Text] [Related]  

  • 29. [Treatment of parkinsonism by L-dopa and dopa-decarboxylase inhibitor in a single tablet].
    Sarova-Pinhas I; Braham J
    Harefuah; 1974 Sep; 87(5):208-10. PubMed ID: 4435614
    [No Abstract]   [Full Text] [Related]  

  • 30. Senile Parkinsonism and dopa pharmacokinetics.
    Broe GA; Evans MA; Triggs EJ
    Clin Exp Neurol; 1981; 18():174-9. PubMed ID: 6926387
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ziprasidone for drug-induced psychotic symptoms in Parkinson's Disease.
    Duggal HS; Singh I
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):583-4. PubMed ID: 18022304
    [No Abstract]   [Full Text] [Related]  

  • 32. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients].
    Hironishi M; Miwa H; Kondo T
    No To Shinkei; 2002 Feb; 54(2):127-32. PubMed ID: 11889758
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Report on 45-month treatment of parkinsonism with L-dopa, alone and in association with a decarboxilase inhibitor (Ro 4-4602).
    Chouza C; Romero S; Gomensoro JB
    Acta Neurol Latinoam; 1974; 20(1-4):116-38. PubMed ID: 4619960
    [No Abstract]   [Full Text] [Related]  

  • 34. Controlled-release carbidopa-levodopa (Sinemet) in combination with standard Sinemet in advanced Parkinson's disease.
    Mark MH; Sage JI
    Ann Clin Lab Sci; 1989; 19(2):101-6. PubMed ID: 2665626
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Parkinsonism following i.v. administration of high-dose metoclopramide used as an antiemetic agent during cancer chemotherapy.
    Markman M; Newman DR; Hawkins RS
    Cancer Treat Rep; 1985 Mar; 69(3):341-2. PubMed ID: 4038919
    [No Abstract]   [Full Text] [Related]  

  • 36. L-dopa, parkinsonism, and involuntary movements.
    Mayer RF
    Trans Am Neurol Assoc; 1974; 99():163-6. PubMed ID: 4463527
    [No Abstract]   [Full Text] [Related]  

  • 37. L-dopa-resistant Parkinsonism due to dopa decarboxylase deficiency?
    Jankovic J
    Ann Neurol; 1981 Jul; 10(1):64-5. PubMed ID: 7271235
    [No Abstract]   [Full Text] [Related]  

  • 38. L-dopa-carbidopa: combined therapy for the treatment of Parkinson's disease.
    Celesia GG; Wanamaker WM
    Dis Nerv Syst; 1976 Mar; 37(3):123-5. PubMed ID: 1253661
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Onset-and end-of-dose dyskinesias induced by L-dopa treatment in a patient with juvenile parkinsonism].
    Katsuki T; Shimizu N; Mizuno Y
    No To Shinkei; 1984 Dec; 36(12):1201-5. PubMed ID: 6529518
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sinemet CR in Parkinson's disease.
    Pfeiffer RF; Wilken KE; Glaeske CS; Hofman R
    Nebr Med J; 1991 Jan; 76(1):8-10. PubMed ID: 1997878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.